| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H21N3O3 |
| Molecular Weight | 363.4097 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=C(C)C=C(C=N1)C2=C(C)C3=C(C=C2)C(=O)C(=CN3C4CC4)C(O)=O
InChI
InChIKey=XPIJWUTXQAGSLK-UHFFFAOYSA-N
InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
| Molecular Formula | C21H21N3O3 |
| Molecular Weight | 363.4097 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Ozenoxacin is an experimental quinolone antibiotic being developed for the treatment of impetigo and other dermatological bacterial infections. Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics. In two phase 3 studies, Ozenoxacin cream, 1%, applied topically twice daily for 5 days vs. placebo, demonstrated superiority on both clinical and bacteriological endpoints, according to the release. Superior bacteriological cure of Ozenoxacin compared to placebo was demonstrated as early as day 4. In both adults and a pediatric population aged 2 months and older, Ozenoxacin treatment was reported to be safe and well tolerated.
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Tox targets
Sourcing
PubMed
Patents
Sample Use Guides
1% cream was applied topically on affected area of 1–100 cm^2 twice dally for 5 days
Route of Administration:
Topical
In vitro development of resistance was carried out using a broth microdilution method by exposing bacteria to stepwise increasing concentrations of T-3912 (Ozenoxacin). Selection of drug-resistant derivatives was carried out by exposure of 5. aureus SA113 and P. ctcnes JCM6425 to stepwise increasing concentrations of T-3912. A series of microtitre wells containing two-fold serial dilutions of T-3912 was inoculated with a final concentration of 10^5 cfu/mL and then incubated for 24 h for S. aureus SA113 and for 48 h for P. acnes JCM6425. In the next step, the well with the highest T-3912 concentration still showing turbidity was used to inoculate a new series of microtitre tray. The procedure was repeated, and the MICs were determined for up to 28 passages.
Showing 1 to 5 of 5 entries
